Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion

NCT ID: NCT00443508

Last Updated: 2007-03-06

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-02-28
• Study Completion Date: 2010-02-28

Brief Summary

This study is design to compare two different strategies aiming to lessen the degree of the ongoing process of allograft injury either by removing tacrolimus from the maintenance immunosuppressive protocol or by reducing tacrolimus dose.

The primary goal is to assess the change in renal function at 6 and 12 months after conversion using creatinine levels and calculated creatinine clearance.

The study will include two groups: The study group of 30 patients and a matched control group with creatinine levels at similar range.

Detailed Description

This study is design to compare two different strategies aiming to lessen the degree of the ongoing process of allograft injury either by removing tacrolimus from the maintenance immunosuppressive protocol or by reducing tacrolimus dose.

The primary goal is to assess the change in renal function at 6 and 12 months after conversion using creatinine levels and calculated creatinine clearance.

The study will include two groups: The study group of 30 patients and a matched control group with creatinine levels at similar range.

Patients will undergo the following baseline studies:

1. Doppler ultrasound to exclude any mechanical or a vascular problem.

2. A kidney biopsy to define the histological changes (degree of interstitial fibrosis, tubular and glomerular changes). The biopsies will be stained also for C4D and for fibrinogenic markers (TGF-beta, and collagen).

3. A 24-hour urine protein excretion and creatinine clearance

4. Echocardiography study

5. Carotid Ultrasound

The following parameters will be monitored every clinic visit throughout the study period:

1. SMA-12 including creatinine levels.

2. A complete blood count.

3. Cholesterol, HDL-cholesterol and triglyceride levels.

4. Blood pressure measurements (X2)

5. The number of blood pressure medications.

6. Cholesterol lowering medication requirement

7. Urine protein excretion (quantitative spot-test )

8. Protein amount in the urine

Study end points:

The data will be evaluated based on an intention to treat analysis and the following parameters will be compared between the two groups:

1. Creatinine levels and calculated creatinine clearance

2. Spot urine for Cr./protein ratio

3. 24-hr. protein excretion

4. Change in peak diastolic and mean arterial blood pressure

5. The number and dosage of blood pressure medications

6. Cholesterol, HDL and triglyceride levels

7. Proportion of patients on cholesterol lowering agents

8. Number and severity of biopsy proven acute rejection episodes

9. Incidence of biopsy proven chronic rejection. (depends on per protocol biopsy at end of study)

10. Patient and graft survival

Conditions

Kidney Diseases

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

adding Certican to therapy

Intervention Type: DRUG

reducing Tacrolimus

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients on CNI FK < 5 ng/m"l with MPA / Imuran with or without steroids
• Renal impairment GFR between 30 - 70 m"l/minute/
• Patient who signed Informed consent
• Patient with no contraindication to renal biopsy
• Women who are not pregnant and will use contraception

Exclusion Criteria

• Proteinuria > 100 m"g/mmol Creatinine
• Acute rejection during 3 months before screening
• WBC < 2500, plt < 50,000,
• Nephropathy due to polyoma virus
• Patients on other investigational drugs
• Patients on rapamycin
• Patients with HIV or other systemic infection
• Inability to comply with protocol requirements
• Active or history of malignancy

• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Novartis

INDUSTRY

Sponsor Role: collaborator

Rabin Medical Center

OTHER

Sponsor Role: lead

Principal Investigators

Eytan Mor, Prof

Role: PRINCIPAL_INVESTIGATOR

Rabin Medical Center, head of Transplantation department

Locations

Transplantation department, rabin Medical Center

Petah Tikva, , Israel

Site Status: RECRUITING

Countries

Israel

Central Contacts

Eytan Mor, Prof

Role: CONTACT

emor@clalit.org.il

00973 3 9376528

Ruti rahamimov, Dr

Role: CONTACT

rutir@clalit.org.il

00973 3 9376528

Facility Contacts

Eytan Mor, Prof

Role: primary

tikim@clalit.org.il

00937 3 9376528

Other Identifiers

CRAD001AIL01

Identifier Type: -

Identifier Source: org_study_id